VG Life Sciences Inc. (VGLS)
Market Closed
16 Jul, 20:00
OTC PINK OTC PINK Primary $
0. 22
0
0%
$
232.26K Market Cap
- P/E Ratio
- Div Yield
120 Volume
0 Eps
$ 0.22
Previous Close Want to track VGLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
VGLS closed Thursday higher at $0.22, an increase of 0% from Wednesday's close, completing a monthly decrease of -46.2927% or -$0.19. Over the past 12 months, VGLS stock gained 220,100.0066%.
VGLS is not paying dividends to its shareholders.
The last earnings report, released on Nov 19, 2015, missed the consensus estimates by -0.01%. On average, the company has fell short of earnings expectations by -0.0133%, based on the last three reports.
VG Life Sciences Inc. has completed 2 stock splits, with the recent split occurring on Apr 16, 2026.
The company's stock is traded on one exchange.
VG Life Sciences Inc. (VGLS) FAQ
What is the stock price today?
The current price is $0.22.
On which exchange is it traded?
VG Life Sciences Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is VGLS.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 232.26K.
Has VG Life Sciences Inc. ever had a stock split?
VG Life Sciences Inc. had 2 splits and the recent split was on Apr 16, 2026.
VG Life Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | William Farrand CEO | OTC PINK Exchange | 91822T200 CUSIP |
| US Country | 1 Employees | - Last Dividend | 16 Apr 2026 Last Split | 16 Nov 1999 IPO Date |
Overview
VG Life Sciences Inc., previously known as Viral Genetics Inc., transformed its name in November 2012 to better reflect its focus and aspirations in the biotechnology industry. Founded in 1995 and nestled in Santa Barbara, California, this ambitious enterprise dedicates itself to the creation of pioneering therapies aimed at confronting formidable adversaries like cancer, infectious diseases, and autoimmune disorders, all of which are frequently driven by chronic inflammation. Operating under the umbrella of Feelux Co., Ltd., VG Life Sciences Inc. merges cutting-edge scientific research with strategic therapeutic applications to address some of the most pressing medical challenges of our time.
Products and Services
- VG1177 - This innovative solution utilizes a synthesized peptide known for its exceptional binding capacities. VG1177 strategically targets and eliminates the Class II-associated invariant chain peptide (CLIP), prevalently shown on specific B cells responsible for chronic inflammation. This approach not only holds potential in minimizing inflammation but also in treating related autoimmune diseases.
- Metabolic Disruption Technology (MDT) Compounds - These compounds are crafted to interfere with the survival mechanisms of tumor cells by disrupting their metabolic processes. This strategy enhances the sensitivity of cancer cells to treatments, making MDT compounds a vital component in the battle against cancer. Among the notable MDT compounds is Hydroxychloroquine, which, when used in conjunction with other cancer medications, shows promise in treating drug-resistant cancers.
- Targeted Peptide Technology (TPT) - TPT represents a groundbreaking technology designed to eradicate a subset of pro-inflammatory immune cells. By doing so, it offers a potential treatment avenue for a host of autoimmune and infectious diseases where inflammation plays a critical role. The precision and targeted nature of this technology underscore VG Life Sciences Inc.'s commitment to innovating in the field of immunotherapy.
Contact Information
Address: 447 Broadway
Phone: 424 224 5358
Website: http://vglscorp.com
